Navigation Links
Lung Infections-Pipeline Insights, 2014
Date:9/3/2014

LONDON, Sept. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Lung Infections-Pipeline Insights, 2014

http://www.reportlinker.com/p02278635/-Lung-Infections-Pipeline-Insights-2014.html

SUMMARY
DelveInsight's," Lung Infections-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Lung Infections. This report provides information on the therapeutic development based on the Lung Infections dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Lung Infections
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Lung Infections pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Lung Infections and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Lung Infections
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Lung Infections pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents
- Lung Infections Overview
- Lung Infections Pipeline Therapeutics
- Lung Infections Therapeutics under Development by Companies
- Lung Infections Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Lung Infections Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Lung Infections Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Lung Infections Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Lung Infections – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Lung Infections – Discontinued Products
- Lung Infections – Dormant Products
- Companies Involved in Therapeutics Development for Lung Infections
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Lung Infections, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Lung Infections Assessment by Monotherapy Products
- Lung Infections Assessment by Combination Products
- Lung Infections Assessment by Route of Administration
- Lung Infections Assessment by Stage and Route of Administration
- Lung Infections Assessment by Molecule Type
- Lung Infections Assessment by Stage and Molecule Type
- Lung Infections Therapeutics – Discontinued Products
- Lung Infections Therapeutics – Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Lung Infections, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Lung Infections Assessment by Monotherapy Products
- Lung Infections Assessment by Combination Products
- Lung Infections Assessment by Route of Administration
- Lung Infections Assessment by Stage and Route of Administration
- Lung Infections Assessment by Molecule Type
- Lung Infections Assessment by Stage and Molecule Type

To order this report: Lung Infections-Pipeline Insights, 2014
http://www.reportlinker.com/p02278635/-Lung-Infections-Pipeline-Insights-2014.html

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>
SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Injury-Pipeline Insights, 2014
2. Lupus Nephritis-Pipeline Insights, 2014
3. Lyme Disease-Pipeline Insights, 2014
4. Lymphedema-Pipeline Insights, 2014
5. Leg Ulcers-Pipeline Insights, 2014
6. Lipodystrophy-Pipeline Insights, 2014
7. Liposarcoma -Pipeline Insights, 2014
8. Liver Cirrhosis-Pipeline Insights, 2014
9. Liver Diseases-Pipeline Insights, 2014
10. Liver Fibrosis-Pipeline Insights, 2014
11. Liver Transplantation-Pipeline Insights, 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... development of Physiocrine-based therapeutics to address severe, rare diseases, today announced ... upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay ... December 14, 2016, at 4:20 p.m. ET. About ... ...
(Date:12/9/2016)... , Dec. 9, 2016 Department of Health ... regulations for medical marijuana dispensaries under Act 16 are ... , and are now available online . ... in the plan for operation; process for dispensing medical ... well as where the dispensary facilities can be located," ...
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
Breaking Medicine News(10 mins):